Clinical Trials Logo

Acid Maltase Deficiency (AMD) clinical trials

View clinical trials related to Acid Maltase Deficiency (AMD).

Filter by:
  • None
  • Page 1

NCT ID: NCT00455195 Completed - Clinical trials for Pompe Disease (Late-Onset)

Late-Onset Treatment Study Extension Protocol

Start date: March 2007
Phase: Phase 4
Study type: Interventional

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The objective of this extension study is to assess the long-term safety and efficacy of alglucosidase alfa treatment in patients with Late-Onset Pompe Disease who were previously treated under the placebo-controlled, double-blind study AGLU02704 (NCT00158600).